Solid Biosciences Inc. (SLDB) — SEC Filings
Solid Biosciences Inc. (SLDB) — 30 SEC filings. Latest: ARS (Apr 23, 2026). Includes 6 10-Q, 5 SC 13D/A, 5 SC 13G/A.
View Solid Biosciences Inc. on SEC EDGAR
Overview
Solid Biosciences Inc. (SLDB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 3, 2025: Solid Biosciences Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $124.5 million, up from $82.1 million in the same period of 2024. This 51.7% increase was primarily driven by a substantial rise in research and development (R&D) expenses, which
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 24 neutral, 2 mixed. The dominant filing sentiment for Solid Biosciences Inc. is neutral.
Filing Type Overview
Solid Biosciences Inc. (SLDB) has filed 1 ARS, 6 10-Q, 4 8-K, 2 DEF 14A, 2 10-K, 5 SC 13D/A, 5 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of SLDB's 13 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 1 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$124.5M |
| Cash Position | $61.4M |
Key Executives
- Ilan Ganot
- Alexander Cumbo
- Alexander Rakitin
- Peter Kolchinsky
- Rajeev Shah
- Dr. Paul B. Markham
- Martin Freed
- Georgia Keresty
- Ian Smith
Industry Context
Solid Biosciences operates in the highly competitive and rapidly advancing gene therapy sector. The industry is characterized by significant R&D investment, long development timelines, and stringent regulatory oversight. Companies are focused on developing novel treatments for rare genetic diseases, with a strong emphasis on clinical trial success and therapeutic efficacy.
Top Tags
biotech (6) · Biotechnology (4) · 10-Q (4) · biotechnology (3) · institutional-ownership (3) · insider-ownership (3) · institutional-investor (3) · amendment (3) · Gene Therapy (2) · Duchenne Muscular Dystrophy (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $124.5M | Increased from $82.1M in 2024 for the nine months ended September 30, 2025 |
| Research and Development Expenses | $102.2M | Increased from $65.7M in 2024 for the nine months ended September 30, 2025 |
| Accumulated Deficit | $908.0M | As of September 30, 2025, up from $783.5M at December 31, 2024 |
| Cash and Cash Equivalents | $61.4M | As of September 30, 2025, down from $80.2M at December 31, 2024 |
| Available-for-Sale Securities | $174.8M | As of September 30, 2025, up from $68.7M at December 31, 2024 |
| Net Cash Provided by Financing Activities | $189.3M | For the nine months ended September 30, 2025, primarily from public offerings |
| Common Stock Shares Outstanding | 77,910,239 | As of October 29, 2025 |
| Total Stockholders' Equity | $217.9M | As of September 30, 2025, up from $137.2M at December 31, 2024 |
| Net Loss for Q2 2025 | $25.2M | Increased from $19.9M in Q2 2024, indicating widening losses. |
| Research and Development Expenses for Q2 2025 | $15.5M | Decreased from $17.0M in Q2 2024, primarily due to reduced SGT-003 costs. |
| General and Administrative Expenses for Q2 2025 | $9.7M | Increased from $7.1M in Q2 2024, driven by higher legal and professional fees. |
| Cash and Cash Equivalents as of June 30, 2025 | $105.3M | Decreased from $130.5M at December 31, 2024, reflecting significant cash burn. |
| Period End Date | 20250331 | The 10-Q covers financial information up to this date. |
| Filing Date | 20250515 | The date the 10-Q was officially submitted to the SEC. |
| Fiscal Year | 2024 | Period covered by the executive compensation disclosures |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Solid Biosciences Inc. (SLDB)?
Solid Biosciences Inc. has 30 recent SEC filings from Jan 2024 to Apr 2026, including 6 10-Q, 5 SC 13D/A, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SLDB filings?
Across 30 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 24 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Solid Biosciences Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Solid Biosciences Inc. (SLDB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Solid Biosciences Inc.?
Key financial highlights from Solid Biosciences Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SLDB?
The investment thesis for SLDB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Solid Biosciences Inc.?
Key executives identified across Solid Biosciences Inc.'s filings include Ilan Ganot, Alexander Cumbo, Alexander Rakitin, Peter Kolchinsky, Rajeev Shah and 4 others.
What are the main risk factors for Solid Biosciences Inc. stock?
Of SLDB's 13 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Solid Biosciences Inc.?
Forward guidance and predictions for Solid Biosciences Inc. are extracted from SEC filings as they are enriched.